Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab phase 2 trial in relapsed or progressive diffuse large B-cell lymphoma
2007-004190-26Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by GSK. Primary endpoint: Objective response. Started Oct 2007; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-004190-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004190-26.